RLAY Stock Analysis: Buy, Sell, or Hold?
RLAY - Relay Therapeutics, Inc. Common Stock
$18.73
-1.27 (-6.37%)
▼
5d:
-0.9%
30d:
+38.84%
90d:
+25.37%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
23d
Smart Money Distribution
None View Scanner →
Strength: 5.6/10
Get Alerted When RLAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RLAY shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RLAY shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RLAY is currently trading at $18.73, which is considered slightly high relative to its 30-day fair value range of $14.69 to $19.26.
Technical Outlook: Technically, RLAY is in a strong uptrend. Immediate support is located at $17.67, while resistance sits at $20.79. Short-term momentum is weak, with the stock down 6.4% recently.
Market Sentiment: RLAY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.08 (+25.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RLAY is in a strong uptrend. Immediate support is located at $17.67, while resistance sits at $20.79. Short-term momentum is weak, with the stock down 6.4% recently.
Market Sentiment: RLAY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.08 (+25.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$14.69 -
$19.26
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
73.7%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.4%)
- BULLISH: Trading 25.4% below Wall St target ($25.08)
Trading Range Analysis
30-Day Trading Range
$14.69 -
$19.26
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$17.67
Resistance Level
$20.79
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.10
Wall Street Target
$25.08
(+25.4%)
Revenue Growth (YoY)
-60.9%
Share & Embed Analysis
Last updated: July 13, 2026 4:21 PM ET
Data refreshes hourly during market hours. Next update: 5:21 PM
Data refreshes hourly during market hours. Next update: 5:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RLAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Thomas Catinazzo
SELL
1800 shares
2026-04-09
Thomas Catinazzo
SELL
17717 shares
2026-04-07
Donald A Bergstrom
SELL
2686 shares
2026-01-28
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 64 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$124 | 61 BUY |
